Stock Analiz

Inhibikase Therapeutics, Inc. (IKT) stock forecast and price target

Price $1.52 · data as of November 13, 2026

12-month price target

Average target$5.55
Upside / downside+265.1%
Analysts10
ConsensusStrong buy
Low $1.50Average $5.55High $8.00

Gold marker: average target · white marker: today’s price ($1.52)

Analyst ratings

Strong buy 1Buy 7Hold 1Sell 0Strong sell 0

Earnings and revenue estimates

PeriodEPS estimateEPS growthRevenue estimate
Current fiscal year
ends December 31, 2026
$-0.40—$0
Next fiscal year
ends December 31, 2027
$-0.41−2.0%$0
Next quarter
ends December 31, 2026
$-0.10—$0
Quarter after
ends March 31, 2027
$-0.10—$0

Consensus of the analysts covering Inhibikase Therapeutics, updated daily. In the last 30 days 0 estimates were raised and 1 lowered.

Frequently asked questions

What is the Inhibikase Therapeutics stock price target?

The average 12-month target from 10 analysts is $5.55, 265.1% above the current price of $1.52 Targets range from $1.50 to $8.00.

Is Inhibikase Therapeutics a buy according to analysts?

The consensus rating is “Strong buy” (1 strong buy, 7 buy, 1 hold). Ratings are opinions, not guarantees; this is not investment advice.

How much is Inhibikase Therapeutics expected to earn?

Analysts expect EPS of $-0.40 for the fiscal year ending December 31, 2026 and $-0.41 the year after.

Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.